Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers.

Doroshyenko O, Rokitta D, Zadoyan G, Klement S, Schläfke S, Dienel A, Gramatté T, Lück H, Fuhr U.

Drug Metab Dispos. 2013 May;41(5):987-93. doi: 10.1124/dmd.112.050203. Epub 2013 Feb 11.

PMID:
23401474
2.

Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps.

Watzek N, Scherbl D, Feld J, Berger F, Doroshyenko O, Fuhr U, Tomalik-Scharte D, Baum M, Eisenbrand G, Richling E.

Mol Nutr Food Res. 2012 Dec;56(12):1825-37. doi: 10.1002/mnfr.201200323. Epub 2012 Oct 27.

PMID:
23109489
3.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U.

Clin Pharmacokinet. 2011 Sep;50(9):551-603. doi: 10.2165/11593320-000000000-00000.

PMID:
21827214
4.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U.

Clin Pharmacokinet. 2011 Jun;50(6):371-403. doi: 10.2165/11587020-000000000-00000. Review.

PMID:
21553932
5.

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.

Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC.

Drug Metab Dispos. 2011 May;39(5):927-32. doi: 10.1124/dmd.110.036921. Epub 2011 Jan 26.

PMID:
21270106
6.

Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Jetter A, Fätkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schömig E, Fuhr U, Wyen C.

Antivir Ther. 2010;15(7):975-83. doi: 10.3851/IMP1648.

7.

Absorption, pharmacokinetics, and safety of triclosan after dermal administration.

Queckenberg C, Meins J, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, Abdel-Tawab M, Fuhr U.

Antimicrob Agents Chemother. 2010 Jan;54(1):570-2. doi: 10.1128/AAC.00615-09. Epub 2009 Oct 12.

8.

Clinical pharmacokinetics and pharmacodynamics of solifenacin.

Doroshyenko O, Fuhr U.

Clin Pharmacokinet. 2009;48(5):281-302. doi: 10.2165/00003088-200948050-00001. Review.

PMID:
19566112
9.

Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

Tomalik-Scharte D, Lütjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U.

Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20.

PMID:
19458613
10.

In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans.

Doroshyenko O, Fuhr U, Kunz D, Frank D, Kinzig M, Jetter A, Reith Y, Lazar A, Taubert D, Kirchheiner J, Baum M, Eisenbrand G, Berger FI, Bertow D, Berkessel A, Sörgel F, Schömig E, Tomalik-Scharte D.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):433-43. doi: 10.1158/1055-9965.EPI-08-0832. Epub 2009 Feb 3.

11.

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.

Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, Jetter A, Lazar A, Klaassen T, Frank D, Wyen C, Fätkenheuer G, Fuhr U.

Eur J Clin Pharmacol. 2008 Oct;64(10):1033-5. doi: 10.1007/s00228-008-0503-9. Epub 2008 Jun 28. No abstract available.

12.

Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops.

Abduljalil K, Diestelhorst M, Doroshyenko O, Lux A, Steinfeld A, Dinslage S, Süverkrüp R, Fuhr U.

Eur J Clin Pharmacol. 2008 May;64(5):521-9. doi: 10.1007/s00228-007-0457-3. Epub 2008 Jan 25.

PMID:
18219479
13.

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

Wyen C, Fuhr U, Frank D, Aarnoutse RE, Klaassen T, Lazar A, Seeringer A, Doroshyenko O, Kirchheiner JC, Abdulrazik F, Schmeisser N, Lehmann C, Hein W, Schömig E, Burger DM, Fätkenheuer G, Jetter A.

Clin Pharmacol Ther. 2008 Jul;84(1):75-82. doi: 10.1038/sj.clpt.6100452. Epub 2008 Jan 9.

14.

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype.

Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, Jetter A, Stehle S, Tsahuridu M, Meineke I, Brockmöller J, Fuhr U.

Clin Pharmacol Ther. 2006 Dec;80(6):657-67.

PMID:
17178266
15.

Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units.

Müller C, Kremer W, Harlfinger S, Doroshyenko O, Jetter A, Hering F, Hünseler C, Roth B, Theisohn M.

Eur J Pediatr. 2006 Apr;165(4):229-39. Epub 2006 Jan 28.

PMID:
16496200
16.

Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers.

Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sörgel F, Klaassen T, Kasel D, Harlfinger S, Doroshyenko O, Frank D, Kirchheiner J, Bräter M, Richter K, Gramatté T, Fuhr U.

Drug Metab Dispos. 2005 Dec;33(12):1859-66. Epub 2005 Sep 23.

PMID:
16183781
17.

Clinical pharmacokinetics of trospium chloride.

Doroshyenko O, Jetter A, Odenthal KP, Fuhr U.

Clin Pharmacokinet. 2005;44(7):701-20. Review.

PMID:
15966754
18.

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sörgel F, Fuhr U.

Antimicrob Agents Chemother. 2005 May;49(5):1733-8.

Supplemental Content

Loading ...
Support Center